Bessemer Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bessemer Group’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,500	Closed	-$21K	–	1943
2018 Q2	$21K	Hold	1,500	–	–	﹤0.01%	1401
2018 Q1	$14K	Hold	1,500	–	–	﹤0.01%	1464
2017 Q4	$6K	Sell	1,500 -1,500	-50%	-$7.15K	﹤0.01%	1555
2017 Q3	$4K	Hold	3,000	–	–	﹤0.01%	1697
2017 Q2	$5K	Hold	3,000	–	–	﹤0.01%	1690
2017 Q1	$8K	Sell	3,000 -12,850	-81%	-$29.7K	﹤0.01%	1569
2016 Q4	$40K	Hold	15,850	–	–	﹤0.01%	1399
2016 Q3	$49K	Hold	15,850	–	–	﹤0.01%	1207
2016 Q2	$51K	Buy	+15,850	New	+$58.1K	﹤0.01%	863

Other funds holding ECYT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bessemer Group's ECYT Position: Q3 2018 in Review

Bessemer Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2018, closing a stake of 1,500 shares — an estimated $21K sold.

Bessemer Group first reported a position in ECYT in Q2 2016 and held it in 9 quarters. The position peaked at $51K in Q2 2016. 139 funds tracked by Wall St. Rank hold ECYT as of Q3 2018.

Bessemer Group reported no remaining Endocyte, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Bessemer Group sold 1,500 Endocyte, Inc. Common Stock shares in Q3 2018, an estimated $21K.
Bessemer Group first reported a position in Endocyte, Inc. Common Stock in Q2 2016 and held it in 9 quarters.
Bessemer Group's Endocyte, Inc. Common Stock position peaked at $51K in Q2 2016.
139 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2018.

Based on Bessemer Group's 13F filing for Q3 2018, filed 6 Nov 2018.